Sionna Therapeutics Inc. Common Stock (SION)
Stock · NASDAQ · Health Care
$3.91as of 10/16/2026
Price chart
Active signals
High Beta27.4%
200 SMA Touch0.0%Resistance level
$5.71
Industry
Biotechnology: Pharmaceutical Preparations
SION Signal Track Record
How signals performed across all stocks →What SION's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 8 | +1.3% | 50% | September 18, 2026 |
| Bollinger Band Breakout | 4 | -46.9% | 0% | August 4, 2026 |
| Bollinger Band Breakdown | 3 | +14.1% | 100% | August 10, 2026 |
| Any 20-session window (baseline) | -1.6% | 44% |
Computed by MarketWall from daily closing prices since November 21, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 59
- Website
- www.sionnatx.com/
Fundamentals
- 1-day range
- $3.78$4.06
- Market cap
- $2.24B
- P/E (trailing)
- —
- P/E (forward)
- -1.74
- EPS (trailing)
- $-2.17
- Dividend yield
- —
- Beta
- 1.48
- Avg. volume
- 2.22M
52-week range
$3.93$54.97
Next earnings: November 5, 2026 · EPS estimate $-0.68confirmed
Forecasts
7 analyst ratings
Buy 35%
Hold 65%
Sell 0%
1-year price forecast
High
$63
+1511.3%
Median
$6
+53.5%
Low
$5
+27.9%
Sionna Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferenceYahoo · 10/8/2026
- Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?Yahoo · 9/17/2026
- SION to Cut Workforce by Nearly Half After CF Study Failure, Stock DownYahoo · 9/16/2026
- FDA clears first generic radioligand drug; Sionna turns to layoffsYahoo · 9/15/2026
- Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program - SlideshowSeekingAlpha · 9/15/2026
- Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6Benzinga · 9/15/2026
- Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program TranscriptSeekingAlpha · 9/15/2026
- Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept TrialYahoo · 9/14/2026
Insider Activity
Insider Actions →Acquired
1.17M
Disposed
894.2K
- Jennifer Fitzpatrick · September 17, 2026 · Disposition103.1K
- Jennifer Fitzpatrick · September 17, 2026 · Grant103.1K
- Jennifer Fitzpatrick · September 17, 2026 · Grant28.1K
- Jennifer Fitzpatrick · September 17, 2026 · Grant28.1K
- McKee Charlotte · September 17, 2026 · Disposition155.7K
- McKee Charlotte · September 17, 2026 · Grant155.7K
- McKee Charlotte · September 17, 2026 · Grant50.0K
- Elena Ridloff · September 17, 2026 · Disposition165.4K
- Elena Ridloff · September 17, 2026 · Grant165.4K
- Elena Ridloff · September 17, 2026 · Grant47.3K
- Elena Ridloff · September 17, 2026 · Grant47.3K
- Cloonan Michael · September 17, 2026 · Disposition436.1K
- Cloonan Michael · September 17, 2026 · Grant436.1K
- Cloonan Michael · September 17, 2026 · Grant109.0K
- RA CAPITAL MANAGEMENT, L.P. · September 17, 2026 · Sale33.8K @ $7.46
Institutional Ownership
March 31, 2026
- Total shares held
- 43.67M
- Total value held
- $1.72B
- Institutional holders
- 117
Top holders this quarter
- Unknown9.91M
- Unknown6.49M
- Unknown3.53M
- Unknown3.20M
- Unknown3.00M
- Unknown2.48M
- Unknown1.45M
- Unknown1.30M
- Unknown1.17M
- Unknown1.03M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible
Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.